BME Renta Variable - Data of PHARMA MAR, S.A.

Date	Hour	Close	Ref.	% Dif.	Last	High	Low	Avg.	Volume	Turnover
26/01/2021	14:52:18	-	87.7500	19.43	104.8000	105.8000	97.0000	101.9982	547,777	55,872,281.20
25/01/2021	Close	87.7500	86.5000	1.45	87.7500	89.5500	87.0000	88.4398	118,569	10,486,223.40

26/01/2021 14:52:31
Bid			Ask
Orders	Volume	Price	Price	Volume	Orders
2	85	104.6000	104.8000	44	1
8	563	104.5000	104.9000	808	7
1	40	104.4000	105.0000	1,265	17
8	604	104.3000	105.1000	343	3
9	976	104.2000	105.2000	784	7

Data Delayed 15 minutes.

1 year
5 years

Last pay

Type	Ex-date	Payment Date	Concept
Dividend	26/06/2020	30/06/2020	Annual 2019

Last split

Date	Equivalence

Last reverse split

Date	Equivalence
22/07/2020	1 x 12

Last capital increase

Period	Proportion	Type
02/06/2017	2 x 1,000	Premium

	2021 until 25/01	2020	2019	2018	2017
Capitalisation * (thousands of euros)	1,610,643	1,303,198	794,858	242,688	552,170
Shares (x 1,000)	18,355	18,355	222,649	222,649	222,649
Period Close Price (euros)	87.7500	71.0000	42.8400	13.0800	29.7600
Period Last Price (euros)	87.7500	71.0000	42.8400	13.0800	29.7600
Period High Price (euros)	91.4000	148.0000	46.1520	33.1440	51.0600
Period Low Price (euros)	71.5500	30.0000	12.9360	10.4520	24.4200
Volume (thousands of shares)	2,578	62,497	26,786	18,457	17,107
Turnover (thousands of euros)	210,895	4,893,224	650,774	348,611	654,106

Profile

Headquartered in Madrid, PharmaMar is a world-leading biopharmaceutical company in the discovery and development of innovative marine-derived anticancer drugs. The company has an important pipeline of drug candidates and a robust R&D oncology program.

PharmaMar develops and commercializes YONDELIS® in Europe and has three clinical-stage programs under development for several types of solid and hematological cancers, PM1183, plitidepsin, and PM60184. PharmaMar is a global biopharmaceutical company with subsidiaries in Germany, Italy, France, Switzerland, United Kingdom and the United States.

PharmaMar fully owns other companies: GENOMICA, Spain's leading molecular diagnostics company; Sylentis, dedicated to researching therapeutic applications of gene silencing (RNAi); and two other chemical enterprises, Zelnova and Xylazel.

To learn more about PharmaMar, please visit us at www.pharmamar.com.

Source: Issuing company.

26/01/2021 00:05:43

Research

Morningstar - Quantitative Report (26 January 2021 08:15) (151 KB)

To obtain detailed information or information in other formats, please contact BME Market Data at marketdata@grupobme.es or visit the website www.bmemarketdata.es.

The information provided by the different websites of Grupo BME is for internal use only. For any commercial use and/or other usage that involves the redistribution of the information to third parties, it is required a prior and express permission from BME Market Data. Please contact us at marketdata@grupobme.es.